Eribulin for Advanced Breast Cancer: A Drug Evaluation / 한국유방암학회지
Journal of Breast Cancer
;
: 12-15, 2013.
Article
in English
| WPRIM
| ID: wpr-36141
ABSTRACT
Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Breast
/
Breast Neoplasms
/
Macrolides
/
Drug Evaluation
/
Ethers, Cyclic
/
Furans
/
Ketones
/
Microtubules
Limits:
Humans
Language:
English
Journal:
Journal of Breast Cancer
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS